Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy

Curr Med Res Opin. 2024 Jan;40(1):87-96. doi: 10.1080/03007995.2023.2287612. Epub 2024 Jan 3.

Abstract

Most patients with schizophrenia need life-long treatment. There is therefore a continued need for effective and tolerable treatment options. A 2-monthly LAI formulation of aripiprazole, Aripiprazole 2-Month Ready-to-Use 960 mg (Ari 2MRTU 960) has recently been approved in the US. Here, the possible role in therapy for this new treatment option is discussed in a narrative review. PubMed was searched for literature on long-acting injectables with a focus on patient-reported outcomes and real-world evidence on extended injection intervals (2-3 months). Dopamine D2 partial agonists, one of which is aripiprazole, exhibit favorable tolerability and safety properties. Additionally, there are many advantages in using long-acting injectable formulations such as enhanced treatment persistence and stability of patients as well as reduced rates of relapses, hospitalizations, and death. Some of these advantages become more pronounced with longer injection intervals. Additional advantages of longer injection intervals are more room for non-medication-related communication between healthcare professionals and patients, patient and physician preferences, reduced caregiver burden, and easier transitioning from inpatient to outpatient treatment. Taken together, since aripiprazole may be a good treatment choice for many patients based on its favorable safety and tolerability profile, and given the advantages of LAI treatment over oral treatment and the advantages of reduced dosing frequency, Ari 2MRTU 960 may become an important treatment option for many clinically stable patients with schizophrenia.

Keywords: Antipsychotic agents; nonpharmacological therapy; patient reported outcome measures.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Aripiprazole / adverse effects
  • Delayed-Action Preparations / therapeutic use
  • Dopamine Agonists / therapeutic use
  • Humans
  • Injections
  • Schizophrenia* / drug therapy

Substances

  • Aripiprazole
  • Antipsychotic Agents
  • Dopamine Agonists
  • Delayed-Action Preparations